The Role of Von Willebrand Factor in the Hemostatic Defect of Acute Promyelocytic Leukemia

References

• Warrell R.P, de The H., Wang Z.Y, Degos L. Acute promyelocytic leukemia. New England Journal of Medicine 1993; 329: 177–189
   PubMed Web of Science ®Google Scholar
• Grignani F., Fagioli M., Alcalay M., Longo L., Pandolfi P.P, Donti E., Biondi A., Lo Coco F., Grignani F., Pelicci P.G. Acute promyelocytic leukemia: from genetics to treatment. Blood 1994; 83: 10–25
   PubMed Web of Science ®Google Scholar
• Alcalay M., Zangrilli D., Fagioli M., Pandolfi P.P, Men-Carelli A., Lo Coco E., Biondi A., Grignani F., Pelicci P.G. Expression pattern of the RARa-PML fusion gene in acute promyelocytic leukemia. Proceeding of the National Academy of Science USA 1992; 89: 4840–4851
   PubMed Web of Science ®Google Scholar
• Tallman M.S., Kwaan H.C. Reassessing the hemostatic disorder associated with acute promyelocytic leukemia. Blood 1992; 79: 543–553
   PubMed Web of Science ®Google Scholar
• Meng-Er H., Yu-Chen Y., Shu-Rong C., Jin-Ren C., Jia-Xiang L., Lin Z., Long-Jun G., Zhen-Yi W. Use of All-Trans-retinoic acid in the reatment of acute promyelocytic leukemia. Blood 1988; 72: 567–572
   PubMed Web of Science ®Google Scholar
• Castaigne S., Chomienne C., Daniel M.T, Ballerini P., Berger R., Fenaux P., Degos L. All-trans retinoic acid as a differentiation therapy for acute promyelocytic leukemia. Blood 1990; 76: 1704–1709
   PubMed Web of Science ®Google Scholar
• Fenaux P., Le Deley C., Castaigne S., , the European APL 91 Group, et al. Effect of all-trans-retinoic acid in newly diagnosed acute promyelocytic leukemia. Results of a multicenter randomized trial. Blood 1993; 82: 3241–3249
   PubMed Web of Science ®Google Scholar
• Degos L., Dombret H., Chomienne C., Daniel M-T., Miclea J-M., Chastang C., Castaigne S., Fenaux P. All-trans- retinoic acid as a differentiating agent in the treatment of acute promyelocytic leukemia. Blood 1995; 85: 2643–2653
   PubMed Web of Science ®Google Scholar
• Warrel R.P, Maslak P., Earldley A., Hellen G., Miller W.H, Frankel S.R. Treatment of acute promyelocytic leukemia with all-trans retinoic acid: an update of the New York experience. Leukemia 1994; 8: 929–933
   PubMed Web of Science ®Google Scholar
• Avvisati G., Lo Coco F., Diverio D., Falda M., Ferrara F., Lazzarino M., Russo D., Petti M.C, Mandelli F. AIDA (All-Trans-Retinoic Acid + Idarubicin) in newly diagnosed acute promyelocutic Leukemia: a Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto (GIMEMA) pilot study. Blood 1996; 88: 1390–1398
   PubMed Web of Science ®Google Scholar
• Dombret H., Scrobohaci M.L, Ghorra P., Zini J.M, Daniel M.T, Castaigne S., Degos L. Coagulation disorders associated with acute promyelocytic leukemia: corrective effect of all-trans retinoic acid treatment. Leukemia 1993; 7: 2–9
   PubMed Web of Science ®Google Scholar
• Kawai Y., Watanabe K., Kizari M., Murata M., Kamata T., Uchida H., Moriki T., Yokoyama K., Tokuhira M., Naka-Jima H., Handa M., Ikeda Y. Rapid improvement of coagulopathy by all-trans retinoic acid in acute promyelocytic leukemia. American Journal of Hematology 1994; 46: 184–188
   PubMed Web of Science ®Google Scholar
• Falanga A., laCoviello L., Evangelista V., Belotti D., Con-Sonni R., D'Orazio A., Robba L., Donati M.B., Barbui T. Loss of blast cell procoagulant activity and improvement of hemostatic variables in patients with acute promyelocytic leukemia administered all-trans retinoic acid. Blood 1995; 86: 1072–1081
   PubMed Web of Science ®Google Scholar
• Falanga A., Marchetti M., Giovanelli S., Barbui T. All-Trans-Retinoic acid counteracts endothelial cell procoagulant activity induced by human promyelocytic leukemia-derived cell line (NB4). Blood 1996; 87: 613–617
   PubMed Web of Science ®Google Scholar
• Andoh K., Kubota T., Takada M., Tanaka H., Kobayashi N., Maekawa T. Tissue factor activity in leukemia cells. Special reference to disseminated intravascular coagulation. Cancer 1987; 59: 748–753
   PubMed Web of Science ®Google Scholar
• Nemerson Y. The tissue factor pathway of blood coagulation. Seminars in Hematology 1992; 29: 170–181
   PubMed Web of Science ®Google Scholar
• Van der Water L., Tracy P.B, Aronson D., Mann K.G, Dvorak H.F. Tumor cell generation of thrombin via profhrombinase assembly. Cancer Research 1985; 45: 5521–5528
   PubMed Web of Science ®Google Scholar
• Falanga A., Gordon S.G. isolation and characterization of cancer procoagulant: a cysteine proteinase from malignant tissue. Biochemistry 1985; 24: 5558–5563
   PubMed Web of Science ®Google Scholar
• Donati M.B, Gambacorti Passerini C., Casali B., Falanga A., Givannotti P., Fossati G., Semeraro N., Gordon S.G. Cancer procoagulant in human tumor cells: evidence from melanoma patients. Cancer Research 1986; 46: 6471–6478
   PubMed Web of Science ®Google Scholar
• Gordon S.G, Hashiba U., Poole M.A, Cross B.A, Falanga A. A cysteine proteinase procoagulant from amnion-chorion. Blood 1985; 66: 1261–1268
   PubMed Web of Science ®Google Scholar
• Wilson E.L, Jacobs P., Dowdle E.D. The secretion of plasminogemn activators by human myeloid leukemic cells in vitro. Blood 1983; 61: 568–575
   PubMed Web of Science ®Google Scholar
• Bennet B., Booth A., Croll A., Dawson A.A. The bleeding disorder in acute promyelocytic leukemia: fibrinolysis due to u-PA rather than defibrination. British Journal of Haematology 1989; 71: 511–519
   PubMed Web of Science ®Google Scholar
• Sakata Y., Murakami T., Noro A., Mori K., Matsuda M. The specific activity of plasminogen activator inhibitor-1 in disseminated intravascular coagulation with acute promyelocytic leukemia. Blood 1991; 77: 1949–1956
   PubMed Web of Science ®Google Scholar
• Browner N.S, Harpel PC. Proteolytic cleavage and inactivation of alpha-2 plasmin inhibitor and C1 inactivator by human polymorphonuclear leukocyte elastase. Journal of Biological Chemistry 1982; 257: 9849–9855
   PubMed Web of Science ®Google Scholar
• Sterrenberg L., Nieuwenhuizen W., Hermans J. Purification and characterization of a D-like fragment from human fibrinogen produced by human leukocyte elastase. Biochimica and Biophysica Acta 1983; 775: 300–306
   Web of Science ®Google Scholar
• Bauer K.A, Rosenberg R.D. Thrombin generation in acute promyelocytic leukemia. Blood 1984; 64: 791–798
   PubMed Web of Science ®Google Scholar
• Watanabe R., Murata M., Takayama N., Tokuhira M., Kizaki M., Okamoto S., Kawai Y., Watanabe K.M, Urakami H., Kikuchi M., Nakamura S., Ikeda Y. Long-term follow-up df hemostatic molecular markers during remission induction therapy with All-trans Retinoic acid for acute promyelocytic leukemia. Thrombosis and Haemos-tasis 1997; 77: 641–645
   PubMed Web of Science ®Google Scholar
• Federici AB, Berkowitz SD, Lattuada A., Mannucci PM. Degradation of von Willebrand factor in patients with acquired clinical conditions in which there is heightened proteolysis. Blood 1993; 81: 720–725
   PubMed Web of Science ®Google Scholar
• Federici A.B, Falanga A., Lattuada A., Di Rocco N., Bar-Bui T., Mannucci P.M. Proteolysis of von Willebrand factor is decreased in acute promyelocytic leukemia by treatment with all-trans-retionioic acid. British Journal of Haematology 1996; 92: 733–739
   PubMed Web of Science ®Google Scholar
• Rugged Z.M, Ware J.L., Ginsburg D. von Willebrand factor. Thrombosis and Hemorrhage, J. Loscalzo, A.I. Schafer, 1994; 16: 305–329, Chapter
   Google Scholar
• Moake J.L, Rudy C.K, Troll J.H, Weinstein M.J, Colan-Nino N.M., Azocar J., Seder R.H, Hong S.H., Deykin D. Unusually large plasma factor VHI/von Willebrand factor multimers in chronic relapsing thrombotic thrombocytopenic purpura. New England Journal of Medicine 1982; 307: 1432–1435
   PubMed Web of Science ®Google Scholar
• Dent J.A, Galbusera M., Ruggeri Z.M. Heterogeneity of plasma von Willebrand factor multimers resulting from proteolysis of the constituent subunit. Journal of Clinical Investigation 1991; 88: 774–782
   PubMed Web of Science ®Google Scholar
• Hamilton K.K, Fretto L.J, Grierson D.S, McKee PA. Effects of plasmin on von Willebrand factor multimers. Degradation in vitro and stimulation of release in vivo. Journal of Clinical Investigation 1985; 76: 261–267
   PubMed Web of Science ®Google Scholar
• Kunicki T.J, Montgomery R.R, Shulleck J. Cleavage of human von Willebrand factor by platelet-calcium activated protease. Blood 1985; 65: 352–358
   PubMed Web of Science ®Google Scholar
• Berkowitz S.D, Nozaki H., Titani K., Murachi T., Plow E.P., Zimmerman T.S. Evidence that calpains and elastase do not produce the von Willebrand factor fragments present in normal plasma and II A von Willebrand disease. Blood 1988; 72: 721–727
   PubMed Web of Science ®Google Scholar
• Berkowitz S.D., Federici A.B. Sialic acid prevents loss of large von Willebrand factor multimers by protecting against amino-terminal proteolytic cleavage. Blood 1988; 72: 1790–1796
   PubMed Web of Science ®Google Scholar
• Budde U., Dent J.A, Berkowitz S.D, Ruggeri Z.M., Zimmerman T.S. Subunit composition of plasma von Willebrand factor in patients with the myeloproliferative syndrome. Blood 1986; 68: 1213–1216
   PubMed Web of Science ®Google Scholar
• Gill J.C, Wilson A.D., Endres-Brooks J., Montgomery R.R. Loss of the largest von Willebrand factor multimers from the plasma of patients with congenital cardiac defects. Blood 1986; 67: 758–761
   PubMed Web of Science ®Google Scholar
• Federici A.B, Berkowitz S.D, Zimmerman T.S, Mannucci P.M. Proteolysis of von Willebrand factor after thrombolytic therapy in patients with acute myocardial infarction. Blood 1992; 79: 38–44
   PubMed Web of Science ®Google Scholar
• Gralnick H.R, Williams S., McKeown L., Kramer W., Krutzsch H., Gorecki M., Pinet A., Garfinkel L.I. A monomelic von Willebrand factor fragment, Leu-504 Ser-728, inhibits von Willebrand factor interaction with glycoprotein Ib-IX. Proceedings of the National Academy of Science U. S. A 1992; 89: 7880–7884
   PubMed Web of Science ®Google Scholar
• Kooistra T., Opdenberg J.P, Toet K., Hendriks H.F.J., van den Hoogen R.M., Emeis J.J. Stimulation of tissue- type plasminogen activator synthesis by retinoids in cultured human endothelial cells and rat tisuues in vivo. Thrombosis and Haemostasis 1991; 65: 565–572
   PubMed Web of Science ®Google Scholar